This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bülow, B. Articles by Erfurth, E. M. Search for Related Content PubMed PubMed Citation Articles by Bülow, B. Articles by Erfurth, E. M.

Postoperative Prognosis in Craniopharyngioma with Respect to Cardiovascular Mortality, Survival, and Tumor Recurrence¹

Departments of Internal Medicine (B.B., E.M.E.), Occupational and Environmental Medicine (R.A., L.H.), Oncology (P.M.), and Neurosurgery (C.-H.N.), University Hospital, Lund, Sweden

Address all correspondence to: Dr. Eva Marie Erfurth, Department of Internal Medicine, University Hospital, S-221 85 Lund, Sweden.

Specific causes of death, survival, and recurrence rates were assessed in a cohort of 60 patients who had undergone surgery for craniopharyngioma between 1951 and 1988. Compared to the general population, the standardized mortality ratio (SMR) was increased [5.55; 95% confidence interval (CI), 3.68–8.22], and it was higher among females (SMR, 11.4) than males (SMR, 4.79). The risk of cardio- and cerebrovascular mortality (SMR, 3.21; 95% CI, 1.29–6.61) was also enhanced. The cumulative survival rates 10 and 15 yr after the initial operation were 68% (95% CI 54–78) and 59% (95% CI 30–63), respectively. A multivariate survival analysis adjusting for age showed a protective effect of radiotherapy (hazard ratio, 0.3; 95% CI, 0.1–0.8) and an increased risk of death after recurrence (hazard ratio, 4.4; 95% CI, 1.4–14), but no obvious effect of radicality at surgery. However, when patients who had died within 6 months after surgery were excluded, no significant protective effect of radiotherapy remained. The cumulative frequency of recurrence after 10 yr was 33% (95% CI, 22–48%), and that after 15 yr was 40% (95% CI, 28–56%). The incidence of recurrence did not differ significantly with respect to age, radicality at surgery, or postoperative radiotherapy. The determinants for long term outcome in patients with craniopharyngioma are interrelated in a complex way, which calls for strict selection criteria in follow-up studies and the use of multivariate statistical models.

This article has been cited by other articles:

				N. Karavitaki, S. Cudlip, C. B. T. Adams, and J. A. H. Wass Craniopharyngiomas Endocr. Rev., June 1, 2006; 27(4): 371 - 397. [Abstract] [Full Text] [PDF]

				O M Dekkers, N R Biermasz, J W A Smit, L E Groot, F Roelfsema, J A Romijn, and A M Pereira Quality of life in treated adult craniopharyngioma patients. Eur. J. Endocrinol., March 1, 2006; 154(3): 483 - 489. [Abstract] [Full Text] [PDF]

				J. Verhelst, P. Kendall-Taylor, E. M. Erfurth, D. A. Price, M. Geffner, M. Koltowska-Haggstrom, P. J. Jonsson, P. Wilton, and R. Abs Baseline Characteristics and Response to 2 Years of Growth Hormone (GH) Replacement of Hypopituitary Patients with GH Deficiency due to Adult-Onset Craniopharyngioma in Comparison with Patients with Nonfunctioning Pituitary Adenoma: Data from KIMS (Pfizer International Metabolic Database) J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4636 - 4643. [Abstract] [Full Text] [PDF]

				P. Kendall-Taylor, P. J Jonsson, R. Abs, E. M. Erfurth, M. Koltowska-Haggstrom, D. A. Price, and J. Verhelst The clinical, metabolic and endocrine features and the quality of life in adults with childhood-onset craniopharyngioma compared with adult-onset craniopharyngioma Eur. J. Endocrinol., April 1, 2005; 152(4): 557 - 567. [Abstract] [Full Text] [PDF]

				J. C. Smith, H. A. Lane, J. Lewis, S. Dann, J. Goodfellow, P. Collins, L. M. Evans, M. F. Scanlon, and J. S. Davies Endothelial Function and Coagulant Factors in Growth Hormone-Treated Hypopituitary Adults Receiving Desmopressin J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 2152 - 2156. [Abstract] [Full Text] [PDF]